Antibodies in 99.3% of youth

With Professor Robert Clancy.Uploaded 21-02-25Link to Quadrant, https://quadrant.org.au/news-opinions/uncategorized/after-covid-now-its-the-lawyers-turn/ Monovalent mRNA XBB.1.5 vaccine effectiveness against COVID-19 hospitalization in Quebec, Canada: impact of variant replacement and waning protection during 10-month follow-uphttps://www.medrxiv.org/content/10.1101/2024.11.13.24317190v1 Protection Conferred by COVID-19 Vaccination, Prior SARS-CoV-2 Infection, or Hybrid Immunity Against Omicron-Associated Severe Outcomes Among Community-Dwelling Adults https://academic.oup.com/cid/article/78/5/1372/7450138 Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United Stateshttps://www.nature.com/articles/s41467-024-45549-9 Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canadahttps://academic.oup.com/cid/article/75/11/1980/6570607COVID-19 mRNA VACCINES: THE PROBLEM THAT WON’T GO AWAY.Emeritus Professor Robert Clancy AMThis month we ‘celebrate’ 5 years since the covid pandemic began in Australia. This is the 10th article I have written for Quadrant on covid pandemic management. Prior to the pandemic my 300+ publications had been in peer reviewed medical journals. Most reported research on airway immune protection which has been my passion for 50 years. In 2019 the University of Newcastle awarded me a Doctor of Science for this work (I was informed that this was the first such award given by the University). My point is that in 2020 with the appearance of SARS-CoV-2 (the virus causing Covid-19), entirely by circumstance, I was as well placed as anyone to understand this new airway infection, its pathogenesis and its management. Specifically, the likely place for vaccination in the control of the pandemic. That is what I did. So, why write 10 articles for Quadrant that were critical of the official response to the pandemic? The answer is a simple one. Everything I had understood about the history of pandemics, the science-based development of an Australian Pandemic Plan, the immunology of mucosal (airway) infections, and the sanctity of the doctor-patient relationship, had been summarily replaced with a narrative centred on a genetic vaccine that had never been used in man, and that did not exist. At this stage the medical press that I had worked with for 50 years had been bought by the narrative and would publish nothing that threatened to compromise it. The legacy press (including its ‘experts’) wore ignorance on a grubby sleeve. But these were the prisms through which medical professionals and the public would learn about the pandemic to inform decisions that affected their patient’s, and their own, health.The narrative made no sense to me. It denied historic experience. It was confused with inherent dangers by neglecting what could be done, while failing to anticipate what might happen. The official Australian Pandemic Plan had been updated in 2019 for an anticipated influenza pandemic. This was modified to cover the new SARS-CoV-2 pandemic early in 2020. Experience with influenza was considered an appropriate model for a pandemic involving a corona virus mutant.How did this narrative conflict with the Plan it replaced? First, it ignored the lessons of epidemiology and science. The corollary was the punitive lockdowns and senseless vaccine mandates. Second, it denied the use of safe, cheap and effective repurposed drugs, decisions that contributed to needless loss of life amongst the most vulnerable. Third and at its centre, it distorted views regarding what could be expected as clinical outcomes of a global mRNA vaccination programme, while minimising concerns an untested genetic vaccine may have unexpected adverse event Learn more about your ad choices. Visit megaphone.fm/adchoices

Covid antibodies found in stored blood samplesUploaded 04-11-22Milan Institute for Tumour Diseases, Coronavirus antibodies, September, 2019Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy (October 2021)https://pubmed.ncbi.nlm.nih.gov/33176598/Full text versionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529295/Screening and Multiple Intervention on Lung Epidemics (SMILEhttps://clinicaltrials.gov/ct2/show/NCT03654105There are no robust data, coronavirus 2 (SARS-CoV-2) infection and spread, prepandemic period worldwideWe investigated the presence of SARS-CoV-2 receptor-binding domain (RBD)-specific antibodiesBlood samples of 959 asymptomatic individuals,enrolled in a prospective lung cancer screening trial,between September 2019 and March 2020Plasma samples repositoryResultsSARS-CoV-2 RBD-specific antibodies were detected in,111 of 959 (11.6%) individualsAll the patients were asymptomatic at the time of blood sample collection.Actual timeframeFirst positive test, 3rd SeptemberSeptember 2019 23/162 (14.2%) October 2019 27/166 (16.3%) Second week of February 2020, (more than 30%)By the end of September, Lombardy, Veneto, Piedmont, Emilia Romagna, Liguria, Lazio, Campania, Friuli.Official timeframeEnd of December 2019, coronavirus 2 identified in Wuhan, Hubei Province, ChinaJanuary 30th 2020 Italy’s first two cases, (two tourists from China tested positive in Rome)February 20, 2020 Lombardy, 38-year-old man, no history of travelAuthorsThis study shows an unexpected very early circulation of SARS-CoV-2 among asymptomatic individualsSeveral months before the first patient was identifiedFinding SARS-CoV-2 antibodies in asymptomatic people before the COVID-19 outbreak in Italy may reshape the history of pandemic.Phenomena 1Underestimation of prevalenceSwabs and serology, focused on symptomatic casesTherefore, an underestimation of overall COVID-19 infections(Selection bias)Therefore overestimation of mortality rateMay 25 and July 15 (2020)SARS-CoV-2 seroprevalence study, n = 64,660Prevalence rate was 2.5%Approximately 1.5 million, (many of whom were asymptomatic)Estimate almost 5 times higher than official reportsPhenomena 2Onset of the epidemic, likely to have preceded identification of the first caseNovember–December 2019Doctors reporting, severe respiratory symptoms in elderly and frail,with atypical bilateral bronchitis, which was attributed to aggressive forms of seasonal influenzaBased on these findings, a prior unnoticed circulation of the virus among the Italian population could be hypothesized.October 2019 to February 2020https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428442/Molecular analysis, PCR, 40 wastewater samples Milan/Lombardy, Turin/Piedmont, and Bologna/Emilia Romagna) Presence of viral RNA,December 18th in Milan and TurinSo, in which direction did the virus travel?7th Military World Games第七届世界军人运动会Commonly known as Wuhan 2019October 18–27, 2019 Around 230,000 volunteers9,308 athletes from 109 countries competing in 329 events Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Direct link to parliament TV, https://parliamentlive.tv/Event/Index/5e1f14d2-72b3-488f-a53c-fc94fee92dac Uploaded 27-01-24Link to Hansard full transcript, https://hansard.parliament.uk/Commons/2024-01-16/debates/152B485D-812D-43CC-9D25-C2B651564810/ExcessDeathTrends?highlight=westminster%20hall#contribution-46059AFE-9A03-472B-9364-0BF972E2E7D8Miriam Cates (Penistone and Stocksbridge) (Con) I will be brief, because it is clear that there is far more demand to speak in the debate than there is time. That shows that we absolutely need a longer debate; we need a debate on the Floor of the House, because it is not just Members present who want to speak, and members of the public have shown enormous interest.I will not go over the excellent points that have been made and the data that has been shared. We know we have a problem in this country with excess deaths, particularly among younger people and particularly from cardiovascular disease. That, in itself, is a huge challenge. We need medical experts and statisticians to address those issues—I am not qualified to do so.What I will say is this: lockdown changed everything. Our response to covid changed everything. Just as we look back on different periods of history—before the war; before the industrial revolution—I believe we will look back at before and after lockdown. Lockdown has changed our economy and how we relate to each other. It has changed our health and our understanding of children’s development.The conditions under which those decisions were made—decisions that were overwhelmingly wrong, in my opinion, although I do not blame any individuals, given the pressure they were under—have not changed. The conditions under which we suspended the precautionary principle, ignored the fact that interventions may cause harm, suspended the importance of children’s education, suspended the safeguarding of children, suspended the need for medical trials and suspended all sorts of safeguards that have stood society in good stead for a long time have not changed.The conditions in Government, the media and wider society under which those decisions were made have not changed because, unfortunately, we have not yet got to the heart of the matter. Why did that pressure come from the media? Why did we have to follow what other countries were doing? Why were we obsessed with particular points of data, such as deaths from covid, rather than considering the wider impact on society?My concern about the covid inquiry is that it is asking all the wrong questions. It is concerned with who swore at whom on WhatsApp, and not the wider conditions under which decisions were made. When, several Education Secretaries ago, the former, former, former Secretary of State for Education, my right hon. Friend the Member for South Staffordshire (Sir Gavin Williamson), stood up in the House of Commons and said that he would close schools, I remember, as a mother, shouting at the television, “Don’t do it! Don’t do it!”. I could see the impact it would have—not just on my own children, but across all the wider components of society. Society is like a big machine; we cannot just take out one part and assume that the rest will continue to operate. We have seen that clearly over the past three years.We must address the reasons why these decisions were made. We cannot do that in three minutes each—we must have a longer debate. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK Uploaded 19-08-21https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/results/new-studieshttps://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdfN = 384,543Households, 221,909Obtaining two vaccine doses remains the most effective way to ensure protection against Delta With Delta, Pfizer-BioNTech and Oxford-AstraZeneca vaccines still offer good protection against new infectionsbut effectiveness is reduced compared with AlphaHowever, Delta infections after two vaccine doses had similar peak levels of virus to those in unvaccinated people(with the Alpha variant, peak virus levels in those infected post-vaccination were much lower)Two doses of either vaccine still provided at least the same level of protection as having had COVID-19 through natural infectionPeople who had been vaccinated after already being infected with COVID-19 had even more protection than vaccinated individuals who had not had COVID-19 beforeTwo doses of Pfizer-BioNTech have greater initial effectiveness against new COVID-19 infectionsbut this declines faster compared with two doses of Oxford-AstraZenecaAfter four to five months, effectiveness of these two vaccines similarhowever, long-term effects need to be studiedThe time between doses does not affect effectiveness in preventing new infectionsYounger people have even more protection from vaccination than older peopleUK, third shotshttps://www.bbc.co.uk/news/live/uk-58266043Prof Peter OpenshawNew and Emerging Respiratory Virus Threats Advisory Group (NERVTAGWe can't just look at the antibody levels and think that that equates to levels of protectionIt still seems that you get a lot of protection from these vaccines, even if the antibody levels have drifted down to some sort of stable level Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

Please share this video, this research must STOP. Gain of function research in the USA today using enhanced potential pandemic pathogen (ePPP) researchUploaded 22-10-22Professor Shmuel Shapira, lead scientist, Israeli Governmenthttps://www.dailymail.co.uk/health/article-11323677/Outrage-Boston-University-CREATES-Covid-strain-80-kill-rate.htmlThis should be totally forbidden, it's playing with fireDr Richard Ebright, Rutgers University, New BrunswickThe research is a clear example of gain of function research.If we are to avoid a next lab-generated pandemic, it is imperative that oversight of enhanced potential pandemic pathogen research be strengthened.it is imperative that officials at US-government agencies,who repeatedly have placed the public at risk by repeatedly violating the existing policies be held accountableProf David Livermore, microbiology, University of East Angliagiven the strong likelihood that the Covid pandemic originated from the escape of a lab-manipulated coronavirus in Wuhan, these experiments seem profoundly unwiseBoston University's National Emerging Infectious Diseases Laboratories is one of 13 biosafety level 4 labs in the USRole of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron14th October 2022Boston University School of Medicinehttps://www.biorxiv.org/content/10.1101/2022.10.13.512134v1Predominant SARS-CoV-2 Omicron variant (BA.1) is highly transmissible, even in fully vaccinated individuals, and causes attenuated disease compared with other major viral variants recognized to dateThe Omicron spike (S) protein, unusually large number of mutations, is considered the major driver of these phenotypesWe generated chimeric recombinant SARS-CoV-2A chimera or chimeric virusOne virus containing genetic material derived from two or more distinct virusesUS Center for Veterinary Biologicshttps://www.aphis.usda.gov/animal_health/vet_biologics/publications/notice_05_23.pdfA new hybrid microorganism,created by joining nucleic acid fragments from two or more different microorganisms,in which each of at least two of the fragments,contain essential genes necessary for replication We generated chimeric recombinant SARS-CoV-2Encoding the S gene of Omicron in the backbone of an ancestral SARS-CoV-2 isolate,and compared this virus with the naturally circulating Omicron variant. The Omicron S-bearing virus robustly escapes vaccine-induced humoral immunity, mainly due to mutations in the receptor-binding motif,yet unlike naturally occurring Omicron, efficiently replicates in cell lines and primary-like distal lung cells. In K18-hACE2 micehttps://www.jax.org/strain/034860K18-hACE2 transgenic mice express human ACE2, including airway epithelia where infections typically begin. Because K18-hACE2 are susceptible to SARS-CoV-2 and SARS-CoV viruses, they are useful for studying antiviral therapies to COVID-19 and SARS.In K18-hACE2 miceOmicron causes mild, non-fatal infection, the Omicron S-carrying virus inflicts severe disease with a mortality rate of 80%. This indicates that while the vaccine escape of Omicron is defined by mutations in S, major determinants of viral pathogenicity reside outside of S.Frankenstein, Mary Shelley, 1818Frightful must it be; for supremely frightful would be the effect of any human endeavour to mock the stupendous mechanism of the Creator of the world (1831 edition) Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices